Neuronal synapse illustration showing neurotransmitter release, symbolizing how BK channel openers restore balance in Fragile X syndrome.

BK Channel Openers: From FRAXA Seed Funding to Big Pharma Investment and Trials

September 11, 2025

See how FRAXA’s early grants propelled Fragile X research from lab discoveries to industry momentum, with partners advancing therapies into trials.

Read More »

BK Channel Openers: A New Hope for Fragile X Treatment – Insights from Kaerus Bioscience CEO Robert Ring

October 22, 2024

Kaerus Bioscience’s BK channel openers for Fragile X syndrome are advancing through Phase 1 trials, offering hope for new treatments with FRAXA’s continued support.

Read More »

BK Channel Openers: A New Drug for Fragile X Is Ready for Clinical Trials

May 31, 2024

A promising new BK channel opener, SPG601 from Spinogenix, is entering clinical trials for Fragile X syndrome. Learn about its potential to restore synaptic function and address core symptoms.

Read More »

Translation-Independent Functions of FMRP in Excitability, Synaptic Transmission and Plasticity

September 12, 2013

With a $140,000 grant from FRAXA Research Foundation, Dr. Vitaly Klyachko and team at Washington University explored STP (short-term plasticity) in Fragile X, namely looking at presynaptic calcium dynamics as a major underlying cause of the STP defects.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (37)